Status:

COMPLETED

Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children

Lead Sponsor:

Tasly Pharmaceutical Group Co., Ltd

Conditions:

Cough

Eligibility:

All Genders

6-14 years

Phase:

PHASE2

Brief Summary

This protocol is designed with the aim of exploring the efficacy of Susu on shortening duration and reducing severity of cough, and observe the safety used in children.

Detailed Description

Susu used to be a clinical experienced Chinese herb formula for treating acute cough caused by common cold. The ingredients includes Hua Ju Hong, Qiao Rui Su, Zi Su Ye, Jie Geng, Gan Cao,which relievi...

Eligibility Criteria

Inclusion

  • Diagnosed as common cold standard, and VAS score of daytime or night-time cough \>= 40mm;
  • Diagnosed as wind cold cough syndrome;
  • Aged 6-14 ( \< 14) years;
  • The course of cough is \<= 48 hours;
  • The maximum temperature is \<= 38 degree C within 24 hours before visit;
  • The informed consent process complies with the requirement,and the legal representative and the child (\>= 8 years old) sign the informed consent form.

Exclusion

  • Accompanied by sore throat, obvious fever;
  • The white blood cell count(WBC), absolute value of neutrophils(NEU) and c-reactive protein(CRP) all exceeded 1.2 times of the upper limit of the reference value, and the researchers considered bacterial infection;
  • With complication, such as otitis media, sinusitis, acute bronchitis, pneumonia;
  • Acute bronchitis, pneumonia have been cured less than 8 weeks;
  • With a medical history of seasonal or perennial allergic rhinitis, chronic sinusitis, chronic otitis media, bronchial asthma, chronic cough or recurrent respiratory tract infection;
  • Patients with severe malnutrition;
  • Patients with other serious systemic diseases of the cardiovascular, brain, liver, kidney and hematopoietic systems, any anatomical or respiratory abnormalities or mental disorders;
  • Allergic to the experimental drugs;
  • Received antihistamines or any cough medicine, oral or inhaled steroid preparation before enrollment;
  • The investigator considers it inappropriate to participate in this clinical trial.

Key Trial Info

Start Date :

September 19 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 24 2022

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT04457011

Start Date

September 19 2020

End Date

February 24 2022

Last Update

September 5 2024

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Xiamen Hospital of Traditional Chinese Medicine

Xiamen, Fujian, China, 361001

2

Hubei Provincial Hospital of TCM

Wuhan, Hubei, China, 430073

3

The First Hospital of Hunan University of Traditional Chinese Medicine

Changsha, Hunan, China, 410007

4

Shanghai Hospital of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, China, 200071